XellSmart Unveils Promising Phase I Results for Off-the-Shelf Parkinson's Disease Cell Therapy

XellSmart presented positive Phase I clinical data for its off-the-shelf cell therapy, XS411, for Parkinson's Disease at the International Congress of Parkinson's Disease and Movement Disorders (MDS). The therapy, an allogeneic cell therapy candidate derived from iPSC-derived dopaminergic neural progenitor cells, demonstrated sustained improvements in motor function, quality of life, and molecular imaging biomarkers. The company also announced full enrollment in its Phase II trial.